CA3088926A1 - Pyridone derivative, composition and use as antiviral drug thereof - Google Patents

Pyridone derivative, composition and use as antiviral drug thereof Download PDF

Info

Publication number
CA3088926A1
CA3088926A1 CA3088926A CA3088926A CA3088926A1 CA 3088926 A1 CA3088926 A1 CA 3088926A1 CA 3088926 A CA3088926 A CA 3088926A CA 3088926 A CA3088926 A CA 3088926A CA 3088926 A1 CA3088926 A1 CA 3088926A1
Authority
CA
Canada
Prior art keywords
ring
carbonyl
hydrocarbyl
page
stereoisomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3088926A
Other languages
English (en)
French (fr)
Inventor
Li Chen
Qing SHAO
Xiaojian XUE
Xiaowen LI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangxi Caishi Pharmaceutical Technology Co Ltd
Original Assignee
Jiangxi Caishi Pharmaceutical Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN201810044308.4A external-priority patent/CN110041327B/zh
Priority claimed from CN201811517425.4A external-priority patent/CN111303147B/zh
Application filed by Jiangxi Caishi Pharmaceutical Technology Co Ltd filed Critical Jiangxi Caishi Pharmaceutical Technology Co Ltd
Publication of CA3088926A1 publication Critical patent/CA3088926A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
CA3088926A 2018-01-17 2019-01-16 Pyridone derivative, composition and use as antiviral drug thereof Pending CA3088926A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201810044308.4A CN110041327B (zh) 2018-01-17 2018-01-17 吡啶酮衍生物、其组合物及作为抗流感病毒药物的应用
CN201810044308.4 2018-01-17
CN201811517425.4A CN111303147B (zh) 2018-12-12 2018-12-12 吡啶酮衍生物、其组合物及作为抗流感病毒药物的应用
CN201811517425.4 2018-12-12
PCT/CN2019/071902 WO2019141179A1 (zh) 2018-01-17 2019-01-16 吡啶酮衍生物、其组合物及作为抗流感病毒药物的应用

Publications (1)

Publication Number Publication Date
CA3088926A1 true CA3088926A1 (en) 2019-07-25

Family

ID=67301986

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3088926A Pending CA3088926A1 (en) 2018-01-17 2019-01-16 Pyridone derivative, composition and use as antiviral drug thereof

Country Status (13)

Country Link
US (1) US11247993B2 (cg-RX-API-DMAC7.html)
EP (1) EP3753936B1 (cg-RX-API-DMAC7.html)
JP (1) JP7352297B2 (cg-RX-API-DMAC7.html)
KR (1) KR102477187B1 (cg-RX-API-DMAC7.html)
CN (4) CN111848615B (cg-RX-API-DMAC7.html)
AU (1) AU2019210414B2 (cg-RX-API-DMAC7.html)
CA (1) CA3088926A1 (cg-RX-API-DMAC7.html)
ES (1) ES3074017T3 (cg-RX-API-DMAC7.html)
PH (1) PH12020551264A1 (cg-RX-API-DMAC7.html)
PT (1) PT3753936T (cg-RX-API-DMAC7.html)
SG (1) SG11202011447UA (cg-RX-API-DMAC7.html)
WO (1) WO2019141179A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202007143B (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2881776T3 (es) 2016-03-08 2021-11-30 Novartis Ag Compuestos tricíclicos útiles para tratar las infecciones por ortomixovirus
JOP20170169A1 (ar) 2016-08-29 2019-01-30 Novartis Ag مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو
US11286262B2 (en) 2017-10-06 2022-03-29 Shionogi & Co., Ltd. Stereoselective process for preparing substituted polycyclic pyridone derivatives
HUE069183T2 (hu) * 2018-02-28 2025-02-28 Novartis Ag 10-(di(fenil)metil)-4-hidroxi-8,9,9a,10-tetrahidro-7H--pirrolo[1',2':4,5]pirazino[1,2-b]piridazin-3,5-dion származékok és kapcsolódó vegyületek mint orthomyxovírus repikáció gátlók influenza kezelésére
WO2020205835A1 (en) * 2019-04-01 2020-10-08 Nikang Therapeutics, Inc. Fused polycyclic pyridone compounds as influenza virus replication inhibitors
CN111909174B (zh) 2019-05-08 2022-01-21 江西彩石医药科技有限公司 吡啶酮衍生物的晶型及制备方法和应用
CN112574170A (zh) * 2019-09-29 2021-03-30 江西东邦药业有限公司 一种二苯并七元环衍生物及其制备方法和应用
CN115135646B (zh) * 2019-12-23 2024-05-17 石家庄迪斯凯威医药科技有限公司 取代的多环化合物及其药物组合物和用途
CN113045589B (zh) * 2019-12-27 2024-08-23 广东东阳光药业股份有限公司 流感病毒复制抑制剂及其用途
CN112898346B (zh) * 2020-01-23 2023-11-10 南京知和医药科技有限公司 水溶性多环化合物及其药物组合物和用途
CN113116899B (zh) * 2020-03-06 2022-12-20 广东众生睿创生物科技有限公司 一种用于治疗流感的药物组合物及含有该药物组合物的制剂
CN111943879A (zh) * 2020-08-03 2020-11-17 南通大学 一种(3s,4r)3-氨基-4(甲氧基甲基)吡咯烷-1-甲酸叔丁酯及其合成方法
CN120289488A (zh) * 2020-08-11 2025-07-11 石家庄迪斯凯威医药科技有限公司 多环化合物及其药物组合物和用途
CN115385932A (zh) * 2021-05-22 2022-11-25 江西彩石医药科技有限公司 吡啶酮衍生物的中间体及其制备方法
CN117003766B (zh) * 2022-10-08 2024-02-02 石家庄迪斯凯威医药科技有限公司 一种抗流感病毒衍生物及其用途
WO2024098856A1 (zh) * 2022-11-09 2024-05-16 石家庄迪斯凯威医药科技有限公司 一种抗流感病毒衍生物及其用途
CN116789556A (zh) * 2023-05-26 2023-09-22 康化(上海)新药研发有限公司 一种含环丙氧基乙胺的制备方法
WO2026145578A1 (zh) * 2024-12-30 2026-07-09 江西科睿药业有限公司 固体分散体、药物组合物及其制备方法与应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5737691B2 (ja) 2009-06-15 2015-06-17 塩野義製薬株式会社 置換された多環性カルバモイルピリドン誘導体
LT2620436T (lt) 2010-09-24 2018-08-10 Shionogi & Co., Ltd. Pakeistojo policiklinio karbamoilpiridono darinio provaistas
CN105764904B (zh) * 2013-09-12 2020-02-11 詹森生物制药有限公司 氮杂-吡啶酮化合物及其用途
CN107709321A (zh) * 2015-04-28 2018-02-16 盐野义制药株式会社 经取代的多环性吡啶酮衍生物及其前药
HK1254961A1 (en) * 2015-12-15 2019-08-02 Shionogi & Co., Ltd. Medicine for treating influenza characterized by comprising combination of cap-dependent endonuclease inhibitor with anti-influenza drug
JP6806413B2 (ja) 2016-02-03 2021-01-06 塩野義製薬株式会社 多環性ピリドン誘導体およびそのプロドラッグ
US10759814B2 (en) * 2016-08-10 2020-09-01 Shionogi & Co., Ltd. Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrug thereof
JOP20170169A1 (ar) 2016-08-29 2019-01-30 Novartis Ag مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو

Also Published As

Publication number Publication date
KR102477187B1 (ko) 2022-12-12
AU2019210414A1 (en) 2020-09-03
SG11202011447UA (en) 2020-12-30
ES3074017T3 (en) 2026-07-16
PT3753936T (pt) 2026-07-10
CN111848616A (zh) 2020-10-30
WO2019141179A1 (zh) 2019-07-25
CN110637016A (zh) 2019-12-31
CN111848615A (zh) 2020-10-30
CN110637016B (zh) 2020-08-18
US20190367517A1 (en) 2019-12-05
EP3753936A1 (en) 2020-12-23
US11247993B2 (en) 2022-02-15
EP3753936B1 (en) 2026-04-08
ZA202007143B (en) 2022-04-28
KR20200118062A (ko) 2020-10-14
CN111848616B (zh) 2021-11-23
CN111848615B (zh) 2022-05-17
JP7352297B2 (ja) 2023-09-28
EP3753936A4 (en) 2022-03-23
CN111848614A (zh) 2020-10-30
CN111848614B (zh) 2021-11-23
JP2021511374A (ja) 2021-05-06
PH12020551264A1 (en) 2021-05-31
AU2019210414B2 (en) 2021-04-01

Similar Documents

Publication Publication Date Title
EP3753936B1 (en) Pyridone derivative, composition thereof and application thereof as anti-influenza drug
US5395839A (en) Imidazopyridine derivatives and their use
CA3008607A1 (en) A medicament for treating influenza characterized by combining a cap-dependent endonuclease inhibitor and an anti-influenza drug
WO2012119941A1 (en) Peptidyl nitrilcompounds as peptidase inhibitors
RU2637945C2 (ru) Производные 1-фенил-2-пиридинил-алкиловых спиртов в качестве ингибиторов фосфодиэстеразы
TWI393708B (zh) 異羥肟酸脂化合物,其用途及其之合成方法
KR101419320B1 (ko) 2-(치환된-아미노)-벤조티아졸 설폰아미드 hiv 프로테아제 저해제
EA029030B1 (ru) Пептидилнитрильные соединения в качестве ингибиторов дипептидилпептидазы i
CN111303147B (zh) 吡啶酮衍生物、其组合物及作为抗流感病毒药物的应用
CA3116830A1 (en) Heteroaromatic compounds as vanin inhibitors
AU2016227618A1 (en) Peptidyl nitril compounds as dipeptidyl peptidase I inhibitors
AU715493B2 (en) Selective beta 3 adrenergic agonists
KR20240154590A (ko) Lpa 수용체 활성과 연관된 상태를 치료하기 위한 화합물 및 조성물
CA3131388A1 (en) Pyrazolopyridine compounds for ire1 inhibition
HK40032909A (en) Pyridone derivative, composition thereof and application thereof as anti-influenza drug
CA2884767A1 (en) Imidazopyridine derivatives
WO2014076038A1 (en) Novel acetamide derivatives as trp channel antagonists
EA045400B1 (ru) Пиридоновое производное, его композиция и применение в качестве противовирусного лекарственного средства
MXPA02002623A (es) Derivados de bencimidazol sustituidos, procedimiento para su preparacion y su empleo como medicamentos.
KR20240089560A (ko) 기질 금속단백질분해효소 저해제로서 유용한 다이아자바이사이클로옥탄 유도체
NZ530154A (en) Naphthothiazine positive allosteric AMPA receptor modulators ( PAARM )

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200716

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241001

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241001

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241001

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D149 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S INTERVIEW

Effective date: 20241106

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20241125

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250131

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250311

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250311

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251210

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251210